Clinical Trial Details
| Trial ID: | L4126 |
| Source ID: | NCT04034524 |
| Associated Drug: | Glp-1 Receptor Agonist |
| Title: | Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: GLP-1 receptor agonist|DRUG: Insulin |
| Outcome Measures: | Primary: Time until first composite CV event (myocardial infarction, stroke), Through Study Completion, an estimated average of 1 year | Secondary: Time until first myocardial infarction, Through Study Completion, an estimated average of 1 year|Time until first stroke, Through Study Completion, an estimated average of 1 year|Time until first serious hypoglycemic event, Through Study Completion, an estimated average of 1 year|Time until first episode of acute pancreatitis, Through Study Completion, an estimated average of 1 year|Time until first episode of acute cholecystitis, Through Study Completion, an estimated average of 1 year | Other: Proportion of patients with HbA1c post-index < 7% (EAGLE), 24 weeks|Proportion of patients with HbA1c post-index < 8% (EAGLE), 24 weeks|Change from baseline HbA1c, Weighted mean, 24 weeks |
| Sponsor/Collaborators: | Sponsor: Brigham and Women's Hospital |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | |
| Enrollment: | 20000 |
| Study Type: | OBSERVATIONAL |
| Study Designs: | Observational Model: |Time Perspective: p |
| Start Date: | 2019-05-01 |
| Completion Date: | 2020-12-31 |
| Results First Posted: | |
| Last Update Posted: | 2020-07-09 |
| Locations: | Brigham and Women's Hospital, Boston, Massachusetts, 02138, United States |
| URL: | https://clinicaltrials.gov/show/NCT04034524 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|